Related Experiment Video
Updated: Jul 2, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Treatment of diffuse large B-cell lymphoma]
B Gleissner1, C Zwick, M Pfreundschuh
1Klinik für Innere Medizin I, Universitätsklinikum Saarland, Homburg. beate.gleissner@uniklinikumk-saarland.de
Abstract:
Diffuse large B-cell lymphoma represent 40% of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are the most important approaches for risk stratification that allows risk adapted modifications of the standard R-CHOP regimen.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy